Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation.

Crusoe EQ, Higashi F, Martinez G, Bittencourt R, Pinto Neto JV, Sousa L, Santucci R, Magalhães RJP, Colli G, Nunes RFM, Ribeiro G, Nicacio J, Zanella KR, Kutner JM, Magalhaes A, Leao D, Hallack Neto AE, Braga W, Souza EG, Guimaraes AJAM, Durigon GS, Laks D, Maiolino A, Hungria VTM; GBRAM- (GRUPO BRASILEIRO DE MIELOMA).

Hematol Transfus Cell Ther. 2019 Aug 12. pii: S2531-1379(19)30118-X. doi: 10.1016/j.htct.2019.05.004. [Epub ahead of print]

2.

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients.

Cury PCC, Higashi F, Zacchi FFS, Palhares RB, Quero AA, Dias ALMS, Crusoé EQ, Hungria VTM.

Hematol Transfus Cell Ther. 2019 Aug 10. pii: S2531-1379(19)30119-1. doi: 10.1016/j.htct.2019.04.006. [Epub ahead of print]

3.

Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center.

Vivas YAV, Hungria VTM, Costa LJM, Dos Santos KB, Chaoubah A, Bustamante-Teixeira MT, Vivas LP, Maiolino A, Neto AEH.

Bone Marrow Transplant. 2019 Aug 30. doi: 10.1038/s41409-019-0659-1. [Epub ahead of print] No abstract available.

PMID:
31471574
4.

Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria.

Ormond Filho AG, Carneiro BC, Pastore D, Silva IP, Yamashita SR, Consolo FD, Hungria VTM, Sandes AF, Rizzatti EG, Nico MAC.

Radiographics. 2019 Jul-Aug;39(4):1077-1097. doi: 10.1148/rg.2019180096.

PMID:
31283452
5.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28.

6.

New proteasome inhibitors in the treatment of multiple myeloma.

Hungria VTM, Crusoé EQ, Bittencourt RI, Maiolino A, Magalhães RJP, Sobrinho JDN, Pinto JV, Fortes RC, Moreira ES, Tanaka PY.

Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):76-83. doi: 10.1016/j.htct.2018.07.003. Epub 2018 Oct 15. Review.

7.

Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.

Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B.

Ann Hematol. 2019 Apr;98(4):941-949. doi: 10.1007/s00277-019-03602-4. Epub 2019 Feb 6.

PMID:
30729281
8.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.

9.

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries.

Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, Garcia DK, Vega GQ, Macias J, Oliveros Alvear JW, Royg M, Neves LA, Lopez Dopico JL, Espino G, Ortiz DR, Socarra Z, Fantl D, Ruiz-Arguelles GJ, Maiolino A, Hungria VTM, Harousseau JL, Durie B.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e43-e50. doi: 10.1016/j.clml.2018.08.005. Epub 2018 Aug 29.

PMID:
30297171
10.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

11.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
12.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
13.

Multiple myeloma and central nervous system involvement: experience of a Brazilian center.

Dias ALMS, Higashi F, Peres ALM, Cury P, Crusoé EQ, Hungria VTM.

Rev Bras Hematol Hemoter. 2018 Jan - Mar;40(1):30-36. doi: 10.1016/j.bjhh.2017.09.004. Epub 2017 Nov 26.

14.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

15.

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission.

Silva LSVD, Crusoe EQ, Souza LRG, Chiattone CS, Hungria VTM.

Rev Bras Hematol Hemoter. 2017 Oct - Dec;39(4):331-336. doi: 10.1016/j.bjhh.2017.05.010. Epub 2017 Jul 1.

16.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28843768
17.

Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.

Jurczyszyn A, Gozzetti A, Gdula-Argasińska J, Czepiel J, Vij R, Fiala M, Valls DJ, Mądry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ.

Ann Hematol. 2017 Oct;96(10):1693-1698. doi: 10.1007/s00277-017-3084-9. Epub 2017 Aug 1.

PMID:
28766002
18.

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG.

Br J Haematol. 2017 Oct;179(1):66-74. doi: 10.1111/bjh.14821. Epub 2017 Jun 27.

PMID:
28653400
19.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

20.

Deacetylase inhibitors: an advance in myeloma therapy?

Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG.

Expert Rev Hematol. 2017 Mar;10(3):229-237. doi: 10.1080/17474086.2017.1280388. Epub 2017 Feb 1. Review.

PMID:
28076695

Supplemental Content

Loading ...
Support Center